Trial Details

Not Recruiting
Basic Information
Clinical ID c2996
Identifier ACTRN12615000855527
Trial Title Investigating whether a targeted nutrient supplement reduces inflammation in people with Inflammatory Bowel Disease
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Inflammatory Bowel Disease (IBD);Crohn's disease; Inflammatory Bowel Disease (IBD) Crohn's disease;Oral and Gastrointestinal - Inflammatory bowel disease;Oral and Gastrointestinal - Crohn's disease
Interventions This study will investigate the a nutritional, targeted refined supplement, to see if this product reduces inflammation, as well as signs and symptoms in adults with IBD. This supplement is made up of Omega 3 fish oil, (more than 500mg); vitamin D:25-OH (500IU); CoQ10 (50mg); zeaxanthin (0.82mg); ,lutein (3mg) and astaxanthin (500mcg). It also contains natural mixed tocopherols, vitamin E with ascorbyl palmitate (1mg). It will be taken orally - 2 capsules a day with the main meal. Adherence is monitored by supplement capsule return. This trial will be conducted as a controlled, double blinded, randomized, cross-over intervention trial over 18 weeks. The duration of the nutritional supplement is 6 weeks, The washout period is 6 weeks.
Participant Information
Sponsor University of Auckland
City -
Country/Region New Zealand
Enrollment Criteria
Sex Requirement ALL
Age Requirement ADULT, OLDER_ADULT
Study Design
Study Type Interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -